OncoMatch/Clinical Trials/NCT05857969
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Is NCT05857969 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Functional Precision Medicine for recurrent childhood acute myeloid leukemia.
Treatment: Functional Precision Medicine — Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Testicular Germ Cell Tumor
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Rhabdomyosarcoma
Sarcoma
Chronic Myeloid Leukemia
Tumor Agnostic
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Nicklaus Children's Hospital · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05857969 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify